May 08, 2013
A Florida federal judge on Wednesday denied Celgene Corp.'s bid to sanction a Teva Pharmaceutical Industries Ltd. unit for pursuing a patent infringement case involving Celgene's bone-marrow cancer drug Vidaza that Celgene calls "frivolous from the outset."